Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656103 | 0.87 | LRRK2 (0.48) | LRRK2CHRM4ENPP1ABCB1ABCC1 | |
| SCHEMBL25656101 | 0.84 | LRRK2 (0.53) | LRRK2CHRM4ENPP1KDM4EALDH1A1 | |
| SCHEMBL25656153 | 0.83 | ENPP1 (0.55) | LRRK2CHRM4ENPP1ABCB1ABCC1 | |
| SCHEMBL25656172 | 0.81 | ENPP1 (0.58) | LRRK2CHRM4ENPP1KDM4EALDH1A1 | |
| SCHEMBL25656157 | 0.81 | ENPP1 (0.58) | LRRK2CHRM4ENPP1 | |
| SCHEMBL25656171 | 0.80 | ENPP1 (0.59) | LRRK2CHRM4ENPP1KDM4EALDH1A1 | |
| SCHEMBL25656194 | 0.79 | ENPP1 (0.78) | LRRK2CHRM4ENPP1 | |
| SCHEMBL25656176 | 0.79 | ENPP1 (0.58) | LRRK2CHRM4ENPP1KDM4EALDH1A1 | |
| SCHEMBL31646863 | 0.78 | CHRM4 (0.64) | LRRK2CHRM4ALDH1A1 | |
| SCHEMBL19889945 | 0.78 | CHRM4 (0.61) | LRRK2CHRM4ABCB1ABCC1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | LRRK2 3715/4885CHRM4 4366/4885ENPP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.